DE69938505D1 - Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren - Google Patents

Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren

Info

Publication number
DE69938505D1
DE69938505D1 DE69938505T DE69938505T DE69938505D1 DE 69938505 D1 DE69938505 D1 DE 69938505D1 DE 69938505 T DE69938505 T DE 69938505T DE 69938505 T DE69938505 T DE 69938505T DE 69938505 D1 DE69938505 D1 DE 69938505D1
Authority
DE
Germany
Prior art keywords
delta
thc
tetrahydrocannabinol
aerosol
elastomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69938505T
Other languages
English (en)
Other versions
DE69938505T2 (de
Inventor
Joanne Peart
Peter Byron
Aron Lichtman
Billy Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Application granted granted Critical
Publication of DE69938505D1 publication Critical patent/DE69938505D1/de
Publication of DE69938505T2 publication Critical patent/DE69938505T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69938505T 1998-10-27 1999-10-20 Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren Expired - Fee Related DE69938505T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10585098P 1998-10-27 1998-10-27
US105850P 1998-10-27
US273766 1999-03-22
US09/273,766 US6509005B1 (en) 1998-10-27 1999-03-22 Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
PCT/US1999/024486 WO2000024362A2 (en) 1998-10-27 1999-10-20 Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use

Publications (2)

Publication Number Publication Date
DE69938505D1 true DE69938505D1 (de) 2008-05-21
DE69938505T2 DE69938505T2 (de) 2009-07-09

Family

ID=26803013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69938505T Expired - Fee Related DE69938505T2 (de) 1998-10-27 1999-10-20 Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren

Country Status (14)

Country Link
US (3) US6509005B1 (de)
EP (1) EP1124551B1 (de)
JP (1) JP2002528399A (de)
KR (1) KR100636854B1 (de)
CN (1) CN1214789C (de)
AT (1) ATE391501T1 (de)
AU (1) AU764119B2 (de)
BR (1) BR9915095A (de)
CA (1) CA2344637A1 (de)
DE (1) DE69938505T2 (de)
ES (1) ES2308855T3 (de)
HK (1) HK1042846B (de)
MX (1) MXPA01004188A (de)
WO (1) WO2000024362A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
CA2382217A1 (en) * 1999-08-20 2001-03-01 Roxane Laboratories, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
WO2001064212A1 (en) * 2000-03-01 2001-09-07 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
GB2361869B (en) * 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
JP5599961B2 (ja) * 2000-03-09 2014-10-01 ジーダブリュー・ファーマ・リミテッド 薬学的組成物
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
GB0025092D0 (en) * 2000-10-13 2000-11-29 Glaxo Group Ltd Medicament dispenser
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
US20030138508A1 (en) * 2001-12-18 2003-07-24 Novack Gary D. Method for administering an analgesic
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1404314A1 (de) * 2001-07-10 2004-04-07 Norton Healthcare Limited Aerosolformulierungen von delta 8 tetrahydrocannabinol
EP1321159A1 (de) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Betätigungsvorrichtung für Druckdosierinhalator mit lasergebohrten Löchern
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
RU2311178C2 (ru) * 2002-04-03 2007-11-27 Солвей Фармасьютикалс Б.В. Композиция, содержащая стабилизированные природные каннабиноиды
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US20080159961A1 (en) * 2002-06-22 2008-07-03 Austen John Woolfe Pharmaceutical Composition
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
ES2370395T3 (es) 2003-05-21 2011-12-15 Alexza Pharmaceuticals, Inc. Utilización de una capa de combustible sólido, procedimiento para fabricarla y unidad de calefacción correspondiente.
AU2004287495A1 (en) * 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
EA200701246A1 (ru) * 2004-12-09 2008-06-30 Инсис Терапьютикс, Инк. Стабильные при комнатной температуре составы дронабинола
CA2599213A1 (en) * 2005-02-25 2006-08-31 Unimed Pharmaceuticals, Inc. Dronabinol compositions and methods of using same
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
CN101198324B (zh) * 2005-06-16 2011-06-08 欧洲凯尔特公司 用于改进剂型的大麻素活性药物成分
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2612019A1 (en) * 2005-06-20 2007-01-04 Unimed Pharmaceuticals, Inc. Dronabinol treatment for migraines
CA2659775A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) * 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
JP2008212436A (ja) 2007-03-06 2008-09-18 Canon Inc 吸入装置
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
JP2009106467A (ja) 2007-10-30 2009-05-21 Canon Inc 吸入装置
US20110038915A1 (en) * 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
WO2012006125A1 (en) * 2010-06-28 2012-01-12 Palliatech Vaporizable substance drug delivery and monitoring system
US8910630B2 (en) 2010-06-28 2014-12-16 Palliatech, Inc. Cannabis drug delivery and monitoring system
EP2654864B1 (de) 2010-12-22 2020-10-28 Syqe Medical Ltd. System zur wirkstofffreisetzung
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US11253472B2 (en) 2012-10-04 2022-02-22 Benuvia Therapeutics Llc Oral cannabinoid formulations
US10265293B2 (en) 2012-10-04 2019-04-23 Insys Development Company, Inc. Oral cannabinoid formulations
US20160151275A1 (en) * 2014-06-16 2016-06-02 James Kevin Shurtleff Method and devices for manufacturing and delivering of aerosolized formulations
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
KR20230117250A (ko) 2014-06-30 2023-08-07 사이키 메디컬 엘티디. 흡입기 장치용 약물 투약 카트리지
RU2690401C2 (ru) 2014-06-30 2019-06-03 Сике Медикал Лтд. Способ и устройство для испарения и ингаляции выделенных веществ
PL3160565T3 (pl) 2014-06-30 2022-01-10 Syqe Medical Ltd. Urządzenia i systemy do dopłucnego dostarczania środków aktywnych
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
AU2015283590B2 (en) 2014-06-30 2020-04-16 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3656427A1 (de) 2014-06-30 2020-05-27 Syqe Medical Ltd. Flussregulierende inhalatorvorrichtung
WO2016054268A1 (en) 2014-09-30 2016-04-07 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
US10660872B2 (en) 2014-11-03 2020-05-26 Ramot At Tel-Aviv University Ltd. Methods for treatment of cognitive decline
WO2016187156A1 (en) * 2015-05-21 2016-11-24 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
US20170038184A1 (en) * 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
ES2874087T3 (es) * 2016-01-06 2021-11-04 Syqe Medical Ltd Tratamiento terapéutico con dosis bajas
IL292514B2 (en) 2016-06-28 2023-10-01 Trichomeshell Ltd Dosage form for administration by vapor and smoking
US9717683B1 (en) * 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
AU2018323861B2 (en) * 2017-08-27 2023-08-17 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
GB2567240B (en) 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
BR112021001323A2 (pt) 2018-07-18 2021-04-20 Glatt Gmbh formulações de liberação prolongada de canabinoides
US20220040141A1 (en) * 2018-10-01 2022-02-10 Blue Harvest, Llc Ultrapure phenol compositions
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CA3171220A1 (en) * 2020-03-19 2021-09-23 Glenn MATTES Dried particle inhalation for delivery of cannabis
US11542226B2 (en) * 2020-04-23 2023-01-03 Axim Biotechnologies, Inc. Polyfunctional cannabinoids
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
GB2595692A (en) 2020-06-03 2021-12-08 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
US20210393576A1 (en) * 2020-06-22 2021-12-23 Jupiter Wellness, Inc. Oronasal cbd formulations and uses thereof
WO2022115718A1 (en) * 2020-11-29 2022-06-02 Castor Trevor P Extraction, separation and purification of cannabinoids from cannabis staiva and other marijuana biomass

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728360A (en) * 1971-08-31 1973-04-17 Little Inc A Ester derivatives of tetrahydrocannabinol
US4087546A (en) * 1976-02-17 1978-05-02 Eli Lilly And Company Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs
US4087547A (en) * 1976-02-17 1978-05-02 Eli Lilly And Company Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma
US4635651A (en) * 1980-08-29 1987-01-13 Jacobs Allen W Process for the inclusion of a solid particulate component into aerosol formulations of inhalable nicotine
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
WO1993011744A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
CA2178473C (en) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5981572A (en) * 1996-05-14 1999-11-09 Glaxo Wellcome Inc. Benzofurans and benzopyrans as chronobiological agents
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
WO1998024420A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
EP0971698A4 (de) * 1996-12-31 2006-07-26 Nektar Therapeutics Aerolisiertes hydrophobisches medikament
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations

Also Published As

Publication number Publication date
JP2002528399A (ja) 2002-09-03
US6509005B1 (en) 2003-01-21
WO2000024362A2 (en) 2000-05-04
CA2344637A1 (en) 2000-05-04
KR100636854B1 (ko) 2006-10-20
US20040258622A1 (en) 2004-12-23
DE69938505T2 (de) 2009-07-09
WO2000024362A3 (en) 2000-08-24
HK1042846B (zh) 2006-01-20
US20020031480A1 (en) 2002-03-14
EP1124551A2 (de) 2001-08-22
KR20010075610A (ko) 2001-08-09
AU764119B2 (en) 2003-08-07
ATE391501T1 (de) 2008-04-15
US6713048B2 (en) 2004-03-30
BR9915095A (pt) 2002-01-15
ES2308855T3 (es) 2008-12-01
AU2143000A (en) 2000-05-15
HK1042846A1 (en) 2002-08-30
MXPA01004188A (es) 2002-06-04
CN1324236A (zh) 2001-11-28
EP1124551B1 (de) 2008-04-09
CN1214789C (zh) 2005-08-17
EP1124551A4 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
DE69938505D1 (de) Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
HK1084941A1 (en) Compounds and their use
HUP0202311A2 (hu) Aeroszollá alakított fertőzésgátló, gyulladásgátló és vértolulást gátló szerek az orrmelléküreg-gyulladás kezelésében
RS20090083A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta -mimetics
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AR036358A1 (es) Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
DE60104399D1 (de) Pulverformulierung zur inhalation
IL168308A (en) Compositions containing roflumilast and formoterol
GB9918559D0 (en) Novel pharmaceutical formulation
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
MY146802A (en) Novel drugs for treating respiratory diseases
HUP0500439A2 (hu) Propofol vízoldható előgyógyszerét tartalmazó vizes alapú gyógyászati készítmények
EA200701805A1 (ru) Состав аэрозоля для дозирующих ингаляторов под давлением
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
WO2006090129A3 (en) Bicalutamide for delivering increasing steady state plasma levels
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
PT1682162E (pt) Utilização de opuntia para a produção de um medicamento para o tratamento da depressão
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee